See the DrugPatentWatch profile for Jelmyto
What's the average cost of Jelmyto in the US?
As of my knowledge cutoff in 2023 [1], the average cost of Jelmyto in the US is around $5,100 for a 6-capsule treatment course, which is used to treat benign prostatic hyperplasia (BPH) and urinary retention. This cost may vary depending on the pharmacy, insurance coverage, and location.
Why has the cost been a topic of discussion among patients?
Patients have expressed concerns about the high cost of Jelmyto, particularly since alternative treatments, such as alpha-blockers and finasteride, are often more affordable and can provide similar benefits. Some patients have also inquired about potential discounts or savings programs offered by Jelmyto's manufacturer, UroGen Pharma.
Has the cost been influenced by patent policies?
According to DrugPatentWatch.com, UroGen Pharma's patents for Jelmyto are set to expire in 2027 and 2028, respectively [2]. If generics or biosimilars enter the market before then, they could potentially lower the cost of the medication.
What's the current landscape of alternative treatments for BPH?
In addition to Jelmyto, patients have various treatment options available, including alpha-blockers (such as tamsulosin), finasteride (Propecia), and other medications like terazosin and dutasteride. These alternatives can be more affordable and may be prescribed off-label or off-patent.
Can savings programs or patient assistance programs help with Jelmyto costs?
Yes, UroGen Pharma offers a patient assistance program that can help with the cost of Jelmyto, including copayment assistance and free medication for eligible patients. Some pharmacies and healthcare organizations may also offer discounts or savings programs.
Sources:
[1] - 2023 Average cost of Jelmyto in the US, GoodRx
[2] - Jelmyto's patents, DrugPatentWatch.com
[3] - UroGen Pharma's patient assistance program, UroGen Pharma's website